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Abstract In addition to the hallmark muscle stiffness, patients with recessive myotonia
congenita (Becker disease) experience debilitating bouts of transient weakness that remain poorly
understood despite years of study. We performed intracellular recordings from muscle of both
genetic and pharmacologic mouse models of Becker disease to identify the mechanism underlying
transient weakness. Our recordings reveal transient depolarizations (plateau potentials) of the
membrane potential to 25 to 35 mV in the genetic and pharmacologic models of Becker
disease. Both Na+ and Ca2+ currents contribute to plateau potentials. Na+ persistent inward
current (NaPIC) through NaV1.4 channels is the key trigger of plateau potentials and current
through CaV1.1 Ca2+ channels contributes to the duration of the plateau. Inhibiting NaPIC with
ranolazine prevents the development of plateau potentials and eliminates transient weakness in
vivo. These data suggest that targeting NaPIC may be an effective treatment to prevent transient
weakness in myotonia congenita.
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Introduction
Myotonia congenita is one of the non-dystrophic muscle channelopathies. It is caused by loss-offunction mutations affecting the muscle chloride channel (ClC-1) (Lipicky et al., 1971;
Steinmeyer et al., 1991; Koch et al., 1992). Patients with recessive myotonia congenita (Becker disease) experience muscle stiffness due to hyperexcitability (Lehmann-Horn et al., 2008;
Trivedi et al., 2014; Cannon, 2015) as well as transient weakness due to unknown factors
(Ricker et al., 1978; Rüdel et al., 1988; Zwarts and van Weerden, 1989; Deymeer et al., 1998;
the CINCH Consortium et al., 2013). Some patients with Becker disease report transient weakness
in arm muscles as a greater impediment than muscle stiffness (Rüdel et al., 1988). This weakness
can last up to 90 s and is brought on by exertion following rest (Ricker et al., 1978; Rüdel et al.,
1988; Zwarts and van Weerden, 1989; Deymeer et al., 1998).
The mechanism underlying transient weakness in Becker disease has remained unknown since its
initial description close to 50 years ago (Ricker and Meinck, 1972). There appears to be loss of muscle excitability, as weakness is accompanied by a drop in compound muscle action potential (CMAP)
amplitude during repetitive stimulation (Ricker and Meinck, 1972; Brown, 1974; Aminoff et al.,
1977; Deymeer et al., 1998; Drost et al., 2001; Modoni et al., 2011). This drop in CMAP is associated with reduction in muscle fiber conduction velocity, which has been proposed to progress to
depolarization block (Zwarts and van Weerden, 1989). What has remained unclear, and perhaps
counterintuitive, is why a loss-of-function mutation of the muscle ClC-1 channels in myotonia
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eLife digest Myotonia is a neuromuscular condition that causes problems with the relaxation of
muscles following voluntary movements. One type of myotonia is Becker disease, also called
recessive myotonia congenita. This is a genetic condition that causes muscle stiffness as a result of
involuntary muscle activity. Patients may also suffer transient weakness for a few seconds or as long
as several minutes after initiating a movement. The cause of these bouts of temporary weakness is
still unclear, but there are hints that it could be linked to the muscle losing its excitability, the ability
to respond to the stimuli that make it contract. However, this is at odds with findings that show that
muscles in Becker disease are hyperexcitable.
Muscle excitability depends on the presence of different concentrations of charged ions
(positively charged sodium, calcium and potassium ions and negatively charged chloride ions) inside
and outside of each muscle cells. These different concentrations of ions create an electric potential
across the cell membrane, also called the ‘membrane potential’. When a muscle cell gets stimulated,
proteins on the cell membrane known as ion channels open. This allows the flow of ions between the
inside and the outside of the cell, which causes an electrical current that triggers muscle contraction.
To better understand the causes behind this muscle weakness, Myers et al. used mice that had
either been genetically manipulated or given drugs to mimic Becker disease. By measuring both
muscle force and the electrical currents that drive contraction, Myers et al. found that the
mechanism underlying post-movement weakness involved a transient change in the concentrations
of positively charged ions inside and outside the cells. Further experiments showed that proteins
that regulate the passage of both sodium and calcium in and out of the cell – called sodium and
calcium channels – contributed to this change in concentration. In addition, Myers et al. discovered
that using a drug called ranolazine to stop sodium ions from entering the cell eliminated transient
weakness in live mice.
These findings suggest that in Becker disease, muscles cycle rapidly between being hyperexcited
or not able to be excited, and that targeting the flow of sodium ions into the cell could be an
effective treatment to prevent transient weakness in myotonia congenita. This study paves the way
towards the development of new therapies to treat Becker disease as well as other muscle ion
channel diseases with transient weakness such as periodic paralysis.

congenita (Lipicky et al., 1971; Steinmeyer et al., 1991; Koch et al., 1992) leads to transient loss
of excitability. The primary defect caused by loss of ClC-1 current is hyperexcitability of muscle,
which causes myotonia.
We established that a ClC-1 homozygous null (ClCadr) mouse model of Becker disease has transient weakness in vivo, mimicking the condition in human patients. Intracellular recording in both
ClCadr muscle and a pharmacologic model of Becker disease (due to block of ClC-1 with 9-AC) have
elucidated a novel phenomenon: transient depolarizations to voltages between 25 and 35 mV,
lasting many seconds, which we termed ‘plateau potentials.’ Blocking Na+ persistent inward current
(NaPIC) with ranolazine prevented both development of plateau potentials and transient weakness.
We conclude that NaPIC plays a central role in the development of plateau potentials, which are the
mechanism underlying transient weakness in Becker disease.

Results
Identification of transient weakness in mice with myotonia congenita
To study in vivo isometric motor performance in the Clcn1adr-mto2J (ClCadr) mouse model of recessive
myotonia congenita (Becker disease), a muscle force preparation that we used previously was
employed (Dupont et al., 2019; Wang et al., 2020). Mice were anesthetized via isoflurane inhalation and the distal tendon of the triceps surae (gastrocnemius, plantaris, and soleus muscles) was dissected free and attached to a force transduction motor; then the sciatic nerve was stimulated with
45 pulses delivered at 100 Hz. In unaffected littermates, there was no myotonia following 45 pulses
at 100 Hz, such that relaxation was immediate (Figure 1A). In ClCadr mice, stimulation with 45 pulses
caused full fusion of force, but relaxation was slowed, due to the presence of myotonia (Figure 1C).
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Figure 1. Transient weakness in the ClCadr mouse model of recessive myotonia. (A) Shown is a force trace from a triceps surae muscle group of an
unaffected littermate in response to stimulation of the sciatic nerve with 45 pulses at 100 Hz. (B) The force trace generated by following the initial
stimulus with 15 pulses at 100 Hz delivered every 4 s. (C) In a ClCadr mouse, following the 45 pulses at 100 Hz (indicated by the dotted vertical line)
there was continued force generation secondary to myotonia. (D) With stimulation every 4 s transient weakness was revealed. (E) Plot of the force
normalized to force at 60 s in unaffected littermates and ClCadr mice. Transient reduction in force was present in ClCadr mice (*, p=0.00015 vs
unaffected littermates at 16 s, t-test, 95% confidence interval 110–114 vs 75–93). n = 5 unaffected littermates and n = 9 ClCadr mice. Error bars represent
± SD.

To determine whether transient weakness was present, the sciatic nerve was additionally stimulated with 15 pulses at 100 Hz every 4 s for 1 min. In unaffected littermates, this caused stable force
production with a mild, gradual reduction that was likely due to fatigue (Figure 1B). In myotonic
mice, the same stimulation protocol revealed transient weakness, as force fell over the first 10–15 s
and then recovered (Figure 1D). To avoid inclusion of fatigue in measurement of transient weakness,
we normalized to force at the end of the 1 min of intermittent stimulation. The plot of the mean normalized force revealed transient weakness, which peaked in severity 15–20 s after the initial stimulation and resolved within 1 min (Figure 1E). These data indicate that transient weakness is present in
ClCadr mice.

Characterization of plateau potentials in genetic and pharmacologic
models of myotonia congenita
In myotonic patients, transient weakness is paralleled by a drop in CMAP amplitude (Ricker and
Meinck, 1972; Modoni et al., 2011). This finding suggests that weakness is due to loss of excitability. To look for inexcitability of ClCadr muscle, intracellular current clamp recordings were performed.
In both unaffected littermates and ClCadr mice, stimulation with a 200 ms injection of depolarizing
current triggered repetitive firing of action potentials during the stimulus. In muscle from unaffected
littermates, the firing ceased as soon as the stimulus was terminated (Figure 2A). In muscle from
ClCadr mice, there was myotonia (continued firing of action potentials following termination of the
stimulus) in 100% of fibers (Figure 2B). The myotonia often persisted for many seconds. While most
runs of myotonia ended with repolarization to the resting membrane potential (Figure 2B), in some
instances, myotonia terminated with the development of depolarizations lasting 5 to >100 s to a
membrane potential near 35 mV (Figure 2C,D). During these prolonged depolarizations, there was
a gradual repolarization of the membrane to near 45 mV, followed by sudden repolarization back
to the resting potential. In some cases, the sudden repolarization was preceded by the development
of oscillations in the membrane potential (Figure 2D). The prolonged depolarizations occurred in
30% of ClCadr muscle fibers (n = 36/119 fibers from 10 mice). Of the 36 fibers with plateau potentials, 26 repolarized to within 4 mV of their initial resting potential. The 10 fibers that did not fully
repolarize may have become damaged and thus were not analyzed.
Depolarizations lasting less than 1 s to a membrane potential close to 60 mV have been
described in a toxin-induced model of hyperkalemic periodic paralysis and were termed plateau
depolarizations (Cannon and Corey, 1993b). While the depolarizations we identified could be due
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Figure 2. Plateau potentials in ClCadr muscle. For A–D, the insets show portions of the traces on an expanded
time base. (A) The response of muscle from an unaffected littermate to injection of 200 ms of depolarizing current
(horizontal bar below the voltage trace); note that action potentials stop when current stops. (B–D) Traces of
myotonia triggered by a 200 ms injection of depolarizing current from three different ClCadr muscle fibers. The
following membrane potentials are identified in C and D: membrane potential prior to stimulation, initial
Figure 2 continued on next page
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Figure 2 continued
membrane potential during the plateau potential, membrane potential prior to the termination of the plateau
potential, and membrane potential following repolarization. (E) Development of a plateau potential during
repetitive stimulation at 8 Hz (stimuli represented by vertical hash marks under the recording).

to similar mechanisms as those described in hyperkalemic periodic paralysis, they seemed more similar to prolonged depolarizations in spinal motor neurons, which can last many seconds, and have
been termed plateau potentials (Alaburda et al., 2002; Heckman and Enoka, 2012; Hounsgaard, 2017). We thus chose the term plateau potentials to describe them.
To determine whether plateau potentials cause inexcitability, ClCadr muscle fibers were stimulated during the plateau phase. During and immediately following plateau potentials, action potential generation in response to current injection failed (Figure 2E). At later times following
repolarization, action potential generation was again possible. The inexcitability at earlier times following repolarization is likely due to slow inactivation of Na channels following the many-second
depolarization (Ruff, 1996; Ruff, 1999; Rich and Pinter, 2003). These data are consistent with the
possibility that plateau potentials and the resultant inexcitability of muscle are the mechanisms
underlying transient weakness in myotonia congenita.
In ClCadr muscle, ClC-1 chloride conductance has been absent throughout development such that
plateau potentials could be a compensatory response to muscle hyperexcitability. To test this possibility, we acutely blocked ClC-1 chloride channels in muscle from unaffected littermates with 100 mM
9-anthracene carboxylic acid (9-AC). This dose of 9-AC blocks more than 95% of ClC-1 chloride
channels in skeletal muscle (Palade and Barchi, 1977) and has been used to model myotonia congenita both in vitro and in vivo (van Lunteren et al., 2011; Desaphy et al., 2013; Desaphy et al.,
2014; Skov et al., 2015). Acute blocking of ClC-1 triggered myotonia and plateau potentials in 92%
of fibers (Figure 3A, 49/53 fibers from eight mice). Following acute block of ClC-1 channels with 9AC, all plateau potentials terminated with sudden repolarization to within 4 mV of the previous resting potential (49/49 fibers). These data strongly suggest that the ion channels responsible for development of plateau potentials are present in wild-type skeletal muscle.
In contrast to the relative consistency in voltage at onset and termination of plateau potentials,
the duration in both the ClCadr and 9-AC treated models of myotonia was highly variable
(Figure 3B, Table 1, variance = 3131 s for ClCadr and 623 s for 9-AC treated muscles). The reason
for the high variance of duration was that the rate of repolarization during the plateau potential varied by more than 100-fold (Figure 3B, Table 1). It was generally not possible to record multiple plateau potentials in individual ClCadr fibers due to the long median duration. However, it was possible
to record multiple plateau potentials within individual fibers of 9-AC treated muscle, as most lasted
only a few seconds. Within individual fibers, the slope of repolarization of plateau potentials was less
variable such that duration was relatively constant with a mean variance of 0.5 s ± 0.7 s (n = 17 9-AC
treated fibers in which four or more plateau potentials were recorded).
In both ClCadr muscle and 9-AC treated muscle, plateau potentials did not occur following every
run of myotonia (Figure 3C). To determine why some runs of myotonia ended in plateau potentials
while others did not, we compared the mean voltage at the end of runs of myotonia that produced
plateau potentials vs. the mean voltage at the end of runs that did not produce plateau potentials,
in 9-AC treated fibers. There was a strong correlation between the mean membrane potential during
the final 500 ms of runs of myotonia and development of plateau potentials. In 22/22 fibers, the
mean membrane potential was more depolarized in runs of myotonia that produced plateau potentials (mean = 40.1 ± 3.1 mV vs 49.0 ± 4.5 mV, p=5  10 11, paired t-test, Figure 3D). This suggested that a voltage-dependent current might be involved. However, another feature of myotonia
that determines whether a plateau potential is triggered is the firing rate, which might correlate with
changes such as build-up of K+ in t-tubules or elevation of intracellular Ca2+. Thus, we examined and
found a strong correlation between the firing rate of myotonia runs and subsequent development of
plateau potentials: In 21/22 fibers, the mean firing rate was higher for runs of myotonia ending in
plateau potentials (mean = 31.2 ± 5.7 Hz vs 23.4 ± 2.9, p=7  10 6, paired t-test, Figure 3E). Thus,
while voltage-dependent channels appear to be involved, changes in ion concentrations due to differences in firing rates remain a possible contributor.
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Figure 3. Characterization of plateau potentials. (A) Three examples of plateau potentials of different duration in 9-AC treated muscle. The 200 ms
current injection is indicated by a horizontal bar underneath the trace. Indicated on each trace is the membrane potential at the start and end of the
plateau potential. (B) The duration of plateau potentials in the ClCadr and 9-AC models of myotonia plotted against the rate of repolarization during the
plateau potential. A linear fit was performed on the log–log plot with an R2 value of 0.98 and a slope of 0.93. (C) Shown are two runs of myotonia from
the same muscle fiber, one ending in a plateau potential and one ending with repolarization. The mean membrane potential and firing rate in the final
500 ms of myotonia (horizontal bar) are indicated by the arrows above each trace. (D) Plot of the average membrane potential during the final 500 ms
of myotonia for 22 fibers in which there were both a run of myotonia ending in a plateau potential and a run ending with repolarization (no plateau
potential). (E) Plot of the average firing rate during the final 500 ms of myotonia for the same 22 fibers.

Another factor that might determine whether plateau potentials are triggered is the duration of
the preceding myotonia. However, recordings of multiple plateau potentials in individual 9-AC
treated muscle fibers did not reveal a consistent pattern of duration of myotonia prior to entry into
plateau potentials (Figure 4). While this does not rule out a contribution of duration of myotonia, it
suggests other factors predominate.
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Table 1. Plateau potential parameters in ClCadrand 9-AC treated unaffected muscle.
Pre-myotonia vm
(mV)

Initial PP vm
(mV)

PP repol slope (mV/ Final PP vm
s)
(mV)

Max repol rate (mV/ Post PP vm
s)
(mV)

Duration of PP
(s)

0.25 ± 0.19
( 0.17)

46.3 ± 2.9
( 46.7)

250 ± 78
(246)

80.4 ± 2.9
( 79.7)

81.9 ± 47.6
(74.4)

45.2 ± 2.3
( 45.1)

197 ± 44+
(192)

80.8 ± 2.9
( 81.6)

11.7 ± 25.0++
(4.1)

ClCadr

80.4 ± 2.9 (-80.0)

35.2 ± 4.2
( 35.8)

9-AC

81.5 ± 2.6 (-82.4)

31.2 ± 3.1*
( 31.4)

3.4 ± 1.8** ( 3.5)

Shown are the mean value ± the standard deviation for parameters of plateau potentials in ClCadr fibers and 9-AC treated fibers. Below the mean value is
the median value in parenthesis. n = 26 fibers with plateau potentials from 10 ClCadr mice and 49 fibers with plateau potentials from eight unaffected
muscles treated with 9-AC. Vm is membrane potential, and repol is repolarization. Pre-myotonia Vm is the resting membrane potential prior to stimulation.
Initial PP Vm is the membrane potential at the beginning of the plateau potential. Final PP Vm is the membrane potential prior to the sudden repolarization terminating the plateau potential. Max repol rate is the maximum rate of repolarization during the sudden repolarization. Post PP Vm is the membrane
potential following termination of the plateau potential. * indicates p<0.05, ** indicates p<1  10 20 of log transformed data. + indicates p<0.01. ++ indicates p<1  10

18

of log transformed data.

Ca2+ and Na+ currents contribute to generation of plateau potentials
To determine whether development of plateau potentials is due primarily to opening or closing of
ion channels, we measured the membrane response to injection of hyperpolarizing or depolarizing
square current pulses at baseline and during plateau potentials. Injection of 5 nA of either depolarizing or hyperpolarizing current during plateau potentials led to variable responses that early in the
plateau potential appeared passive, but prior to repolarization triggered an overshoot of membrane
potential after termination of current injection (Figure 5). The presence of an overshoot fits with the
propensity of membrane potential to oscillate prior to termination of plateau potentials (Figure 2D).
Since the response appeared passive during the early phase of plateau potentials we estimated relative input resistance, which was reduced by 50% following initial depolarization versus baseline
(0.43 ± 0.05 vs 0.90 ± 0.12 MW, p<0.01, paired t-test, n = 14 fibers). While caution must be used in
interpreting these data, they favor the possibility that there is a net increase in membrane conductance during the early phase of plateau potentials.
One possible explanation for the overshoot in voltage following termination of current injection
during the late phase of plateau potentials is voltage-dependent opening and closing of KV channels. The voltage near the end of plateau potentials is near the midpoint of activation of rodent skeletal muscle KV channels (Beam and Donaldson, 1983). With the injection of hyperpolarizing current,
KV channels would be caused to close, resulting in a depolarizing overshoot following termination of
current injection. With the injection of depolarizing current, the converse would happen. This may
not occur during the initial phase of plateau potentials if KV channels are mostly open or inactivated
(DiFranco et al., 2012).
The finding that membrane conductance is increased during the initial phase of plateau potentials
suggests opening of either Ca2+ or Na+ channels. In spinal motor neurons, L-type Ca2+ channels
play a central role in generation of plateau potentials (Alaburda et al., 2002; Heckman and Enoka,
2012; Hounsgaard, 2017). To determine whether Ca2+ current through skeletal muscle L-type channel (Cav1.1) triggers plateau potentials, we performed recordings on skeletal muscle fibers from a
mouse model (ncDHPR) in which the pore region of Cav1.1 carries a point mutation leading to ablation of inward Ca2+ current (Dayal et al., 2017). We used voltage clamp of FDB/IO fibers to verify
the absence of inward currents in ncDHPR mice. In wild-type littermate controls, ramp depolarization
following block of Na+, K+, and Cl channels triggered a large, inward Ca2+ current, which began to
activate at 15.1 ± 6.9 mV (n = 4 fibers) with a mean amplitude of 165 ± 46 nA (Figure 6A,B). Ramp
depolarization triggered no inward Ca2+ current in ncDHPR muscle fibers (mean = 0 ± 0 nA, n = 10
fibers; Figure 6C).
To determine whether current flow through Cav1.1 contributes to generation of plateau potentials, current clamp recordings were performed. Application of 100 mM 9-AC led to
the development of plateau potentials in 41/49 fibers from four wild-type mice and in 47/49 fibers
from three ncDHPR mice (Figure 6D and E). Analysis of the characteristics of plateau potentials suggests that Ca2+ current flow through Cav1.1 channels influences the duration of the plateau. While
there was no difference in the beginning or ending voltages of plateau potentials, the duration was
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Figure 4. Lack of correlation between duration of myotonia and development of plateau potentials. Exemplary
prolonged intracellular recordings of plateau potentials from 9-AC treated muscle fibers (n = 5 fibers). There is no
consistent relationship between duration of myotonia and development of plateau potentials. The horizontal lines
under each trace mark 200 ms injections of depolarizing current.

shorter in ncDHPR muscle (Figure 6D and E, Table 2). The cause of the shorter plateau potential
was an increase in the rate of repolarization (Table 2). These data suggest that Ca2+ influx through
Cav1.1 does not play a role in the initiation of plateau potentials, but is involved in sustaining them.
The Nav1.4-mediated Na+ current responsible for the generation of action potentials in skeletal
muscle inactivates within ms of depolarization, making it highly unlikely that it contributes to development of plateau potentials. However, a Na+ current lacking fast inactivation (NaPIC) was found to
be involved in the generation of plateau depolarizations in muscle in a toxin model of hyperkalemic
periodic paralysis (Cannon and Corey, 1993b). We recently determined that NaPIC contributes to
repetitive firing occurring during myotonia (Hawash et al., 2017; Metzger et al., 2020). NaPIC is
present in normal skeletal muscle and likely derives from modal gating in which a small subset of
Nav1.4 channels reversibly enter a mode lacking fast-inactivation (Patlak and Ortiz, 1986;
Gage et al., 1989). We term the Na+ channels responsible for action potentials ‘fast-inactivating
Na+ channels’ and Na+ channels lacking fast inactivation ‘NaPIC’.
To determine whether NaPIC might play a role in the generation of plateau potentials, we
applied ranolazine to 9-AC treated muscle. Ranolazine has been found to preferentially block NaPIC
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Figure 5. Reduced input resistance during the early phase of plateau potentials. Shown are recordings with 200
ms injections of hyperpolarizing (top) or depolarizing (bottom) current during two plateau potentials from a 9-AC
treated fiber. Insets show the trace on an expanded voltage and time axis (scale bars of insets 4.0 mV and 0.02 s).

in brain, heart, peripheral nerve, and skeletal muscle (El-Bizri et al., 2011; Kahlig et al., 2014). We
previously found that ranolazine was effective in eliminating myotonia by blocking NaPIC while sparing enough fast-inactivating Na+ channels to allow for repetitive firing of action potentials triggered
by current injection (Novak et al., 2015; Hawash et al., 2017). As shown in Figure 7A, when myotonia was triggered by the treatment of muscle with 9-AC, 94% of fibers (n = 53 fibers from eight
mice) developed plateau potentials in response to a 200 ms injection of depolarizing current. Following treatment with 40 mM ranolazine, 0/22 fibers from three mice developed plateau potentials after
200 ms current injection (Figure 7A, p<0.01 vs untreated). These data were consistent with NaPIC
playing a role in the development of plateau potentials.
However, as myotonia was greatly reduced by ranolazine (Novak et al., 2015; Hawash et al.,
2017), it was possible that elimination of plateau potentials was secondary to a reduction in the
number of myotonic action potentials. We thus changed our stimulation protocol to a 2 s train of 3
ms stimulus pulses delivered at 20 Hz. This firing rate and duration of firing mimics the duration and
rate of firing during runs of myotonia (Hawash et al., 2017). For trains of stimuli, the amplitude of 3
ms pulses of current were first adjusted to find the lowest current required to elicit an action potential. The current was then increased by 10 nA prior to delivering a train of stimuli. 2 s of 20 Hz stimulation triggered plateau potentials in 46/55 fibers (n = 5 mice, Figure 7B). Out of the 46 fibers with
plateau potentials triggered by 20 Hz trains of stimuli, 11 fibers entered plateau potentials with limited (three or less myotonic APs) or no myotonia. When 40 mM ranolazine was applied, plateau
potentials developed in 0/68 fibers (n = 5 mice, p<0.01 vs untreated, Figure 7B). These data suggest that ranolazine is not eliminating plateau potentials via a secondary effect of prevention of
repetitive firing.
As shown in Figure 3C and D, the mean membrane potential at the end of a run of myotonia correlated with whether myotonia terminated in a plateau potential or with repolarization. Thus, we
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Figure 6. Current flow through Cav1.1 does not initiate, but helps to sustain, plateau potentials in 9-AC treated muscle. (A) The voltage protocol
applied to FDB/IO fibers consisted of a ramp depolarization from 85 mV to +10 mV applied over 8 s. (B) A large inward current is present in wild-type
muscle when Na+, K+, and Cl currents were blocked. (C) ncDHPR muscle fibers confirm the absence of inward Ca2+ current as there is only the linear
change in current due to the changing command potential. (D) A plateau potential in a 9-AC treated wild-type muscle fiber. (E) A plateau potential in a
9-AC treated ncDHPR fiber.

tested if ranolazine prevented plateau potentials by hyperpolarizing the mean membrane potential
prior to the development of plateau potentials. Untreated fibers with additional action potentials
and plateau potentials occurring during the 2 s stimulation (myotonia) were excluded from
the analysis to ensure that the presence of myotonia or plateau potentials did not account for the
difference in mean membrane potential. As all untreated fibers initially had plateau potentials or

Table 2. Plateau potential parameters in 9-AC treated wild-type and ncDHPR muscle.
Pre-myotonia vm
(mV)

Initial plateau vm
(mV)

PP repol slope
(mV/s)

Final PP vm
(mV)

Max repol rate
(mV/s)

Post PP vm
(mV)

Duration of PP
(s)

Wild type

79.3 ± 0.9
( 79.5)

36.0 ± 1.6
( 36.0)

3.3 ± 0.7
( 3.1)

48.1 ± 1.2
( 48.5)

125 ± 6
(125)

79.5 ± 0.4
( 79.7)

3.9 ± 0.7
(3.8)

ncDHPR

78.9 ± 0.6
( 79.0)

37.2 ± 0.8
( 37.1)

5.4 ± 0.6*
( 5.3)

49.2 ± 1.1
( 49.7)

134 ± 10
(138)

79 ± 0.8
( 79.3)

2.4 ± 0.3*
(2.3)

Shown are the mean value and the standard deviation for parameters of plateau potentials in 9-AC treated wild-type and ncDHPR fibers. Below the mean
value in parentheses is the median value. n = 41 fibers from four wild-type mice and n = 47 fibers from three ncDHPR mice. Vm is membrane potential,
and repol is repolarization. Pre-myotonia Vm is the resting membrane potential prior to stimulation. Initial PP Vm is the membrane potential at the beginning of the plateau potential. Final PP Vm is the membrane potential prior to the sudden repolarization terminating the plateau potential. Max repol rate
is the maximum rate of repolarization during the sudden repolarization. Post PP Vm is the membrane potential following termination of the plateau potential. * indicates p=0.01 for both significant differences (t-test).
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Figure 7. Block of plateau potentials by ranolazine in 9-AC treated muscle is associated with lessening of depolarization during repetitive firing. (A)
Examples of the response to a 200 ms injection of depolarizing current at baseline and following treatment with 40 mM ranolazine. (B) Examples of the
response to 2 s of stimulation at 20 Hz. The vertical arrow points to the 30th action potential in each trace, which was used for the analysis of
differences between ranolazine untreated and ranolazine treated muscle (D–F). (C) Plots of the membrane potential during the 8 ms encompassing the
Figure 7 continued on next page
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Figure 7 continued
action potential and the 42 ms encompassing the interspike interval for the untreated and ranolazine traces shown in B. Each point represents the value
for a single action potential during the 2 s of 20 Hz stimulation. Action potential MP = the mean membrane potential during the 8 ms encompassing
the action potential, Inter-AP MP = the mean membrane potential during the 42 ms interspike interval. (D) Plot of the mean membrane potential during
the last 500 ms of stimulation. Each point represents an animal average derived from at least four fibers without (n = 5) and with treatment with
ranolazine (n = 5). The horizontal line represents the mean. (E and F) Plots of the mean membrane potential during the 30th action potential and the
30th interspike interval. * indicates p=0.005 (t-test), **p=0.01 (t-test).

myotonia during repetitive stimulation, the analysis was not possible. To address this issue, the
warm-up phenomenon was induced using 8 Hz 10 s trains, which lessens myotonia due to slow inactivation of Na channels (Novak et al., 2015). It must thus be noted that the untreated muscle was
not at baseline but had already undergone some Na channel inactivation. No induction of warm-up
was necessary following treatment with ranolazine, as no fibers had myotonia or plateau potentials.
In the absence of ranolazine, the mean membrane potential during the 500 ms prior to the plateau
potential was 49.6 ± 2.5 mV (n = 5 muscles, 28 fibers). In the presence of 40 mM ranolazine, the
mean membrane potential was less depolarized ( 56.2 ± 2.9 mV, p<0.05 vs untreated, n = 5
muscles, Figure 7D). These data suggest that ranolazine prevents plateau potentials by lessening
depolarization of the mean membrane potential during the 20 Hz stimulation.
There are two contributors to the mean membrane potential during repetitive stimulation: (1) the
membrane potential during action potentials, and (2) the membrane potential during the interspike
interval. We analyzed the contribution of each of these to the hyperpolarization caused by ranolazine. By the 30th action potential of the 20 Hz stimulation, action potential duration had increased
to close to 8 ms. This widening of the spike-form was likely due to failure of the membrane potential
to fully repolarize between action potentials, given that depolarization has previously been found to
cause widening of action potentials (Renaud and Light, 1992; Yensen et al., 2002; Miranda et al.,
2017). We examined the mean membrane potential during the 8 ms encompassing the 30th action
potential and found a trend (not statistically significant) toward lessening of depolarization following
treatment with ranolazine (Figure 7C,E: 28.2 ± 3.4 vs 32.9 ± 3.8 mV, p=0.07). With 20 Hz stimulation, there is an action potential every 50 ms. After taking the mean membrane potential for the 8
ms encompassing the 30th action potential, there remained 42 ms in which there was no action
potential. The membrane potential for this 42 ms interspike interval before the 30th action potential
was less depolarized following treatment with ranolazine (Figure 7C,F: 56.0 ± 2.3 vs 61.7 ± 3.0
mV, p<0.05). As the interspike interval accounts for 84% (42/50ms) of the time between spikes during 20 Hz stimulation, hyperpolarization of this interval is largely responsible for hyperpolarization of
the mean membrane potential.

Ranolazine prevents transient weakness in vivo
The finding that ranolazine eliminates plateau potentials allowed us to explore whether plateau
potentials are the mechanism underlying transient weakness in vivo. We recorded triceps surae force
in 5 ClCadr myotonic mice before and 45 min after intraperitoneal (i.p.) injection of 50 mg/kg of ranolazine. As shown previously (Novak et al., 2015), treatment with ranolazine decreased myotonia
such that muscle was able to more rapidly relax following termination of stimulation (Figure 8A). In
addition to lessening myotonia, treatment with ranolazine eliminated transient weakness in all five
mice (Figure 8A and B, p<0.01 vs untreated at 16 s). The elimination of both plateau potentials and
transient weakness by ranolazine supports the hypothesis that plateau potentials are the mechanism
underlying transient weakness in vivo.

Discussion
Motor dysfunction in recessive myotonia (Becker disease) involves both muscle stiffness and transient
weakness. Using intracellular recordings from a mouse model of myotonia congenita (ClCadr), we discovered that while some runs of myotonia resolved with repolarization, others terminated with a plateau potential; that is, depolarization to a membrane potential between 30 and 45 mV, lasting
up to 100 s. There was gradual repolarization during plateau potentials until the membrane potential
reached 45 mV, at which point a sudden repolarization to the resting membrane potential
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Figure 8. Ranolazine eliminates transient weakness in vivo. (A) Shown are the force traces from a triceps surae muscle group before and 45 min after
i.p. injection of 50 mg/kg ranolazine. (B) Shown is the mean normalized force in 5 ClCadr mice before and after injection of ranolazine. p=0.001 for the
difference in force 16 s (*) after the initial stimulation (paired t-test, 95% confidence interval 70–86 vs 102–113). The unaffected littermate data from
Figure 1 is replotted here to allow for comparison.

occurred. During plateau potentials, muscle fibers were inexcitable. Studies of genetic and pharmacologic mouse models suggest both current through voltage-activated CaV1.1 Ca2+ channels and
NaPIC may contribute to plateau potentials. NaPIC through NaV1.4 channels is the key trigger of
plateau potentials and current through CaV1.1 Ca2+ channels contributes to sustaining plateau
potentials. Blocking NaPIC with ranolazine eliminated both plateau potentials in vitro and transient
weakness in vivo. Our results suggest that plateau potentials are the mechanism underlying transient
weakness in Becker disease.

Rapid transition between hyperexcitability and inexcitability in Becker
disease
Our data suggest that muscle from a mouse model of Becker disease undergoes a rapid transition
between the states of hyperexcitability (myotonia) and inexcitability (due to plateau potentials),
shown in Figure 9. Repeated firing of action potentials during voluntary contraction triggers myotonia, which often transitions to a depolarization that forms a plateau potential. During plateau potentials, fibers cannot generate action potentials in response to stimulation, providing an explanation
for the drop in CMAP amplitude reported in patients (Ricker and Meinck, 1972; Brown, 1974;
Aminoff et al., 1977; Deymeer et al., 1998; Drost et al., 2001; Modoni et al., 2011). The reason
for the rapid transition between myotonia (hyperexcitability) and plateau potentials (inexcitability) is
that both states are caused by depolarization secondary to loss of muscle Cl- current. The difference
is one of degree: when depolarization is mild, Na+ channels are not inactivated, such that repetitive
firing of action potentials is triggered. When depolarization worsens, Na+ channels inactivate, such
that inexcitability and paralysis ensue. This proposal is similar to the current understanding of hyperkalemic periodic paralysis, in which there is often myotonia at the beginning of attacks (during the
initial, mild depolarization) and weakness at the height of an attack (when depolarization is maximal)
(Cannon, 2015; Statland et al., 2018).

Ion channels contributing to generation and maintenance of plateau
potentials
Involvement of voltage-gated channels in the generation of plateau potentials is suggested by the
strong correlation between membrane potential and the initiation and termination of plateau potentials. In runs of myotonia that terminated in a plateau potential, the mean membrane potentials averaged to include both action potentials and interspike intervals prior to development of a plateau
potential was 40 mV, whereas, within the same fibers, runs of myotonia terminating with repolarization had a mean membrane potential prior to repolarization of 49 mV. The midpoint of the
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Figure 9. Voluntary contraction in myotonia congenita triggers a sequential progression through states of hyperexcitability and inexcitability. Shown on
the left is a motor unit consisting of a motor neuron and the muscle fibers it innervates. At rest, both the motor neuron and muscle fibers are
hyperpolarized and muscle is relaxed. To initiate voluntary contraction, the motor neuron fires repeated action potentials, which activate the
neuromuscular junction (NMJ) to trigger repeated firing of action potentials in muscle (indicated by a yellow outline around the fiber). With the rapid
firing of muscle action potentials, there is sustained contraction and force production (blue line). At the end of voluntary contraction, the motor neuron
stops firing and the NMJ repolarizes, but in myotonic muscle there is continued involuntary firing of action potentials, which slows relaxation of muscle.
When myotonia is terminated by transition into a plateau potential, muscle remains depolarized but cannot fire action potentials (black outline of the
fiber), such that muscle is paralyzed. Finally, there is sudden repolarization and return of muscle to the resting state. Under the voltage trace our
hypothesis regarding the contribution of NaPIC and current through CaV1.1 channels is illustrated. NaPIC begins to turn on at the end of voluntary
contraction and triggers myotonia. In some runs of myotonia, NaPIC continues to increase and contributes to initiation of plateau potentials. The initial
plateau potential voltage is sufficiently depolarized to trigger opening of CaV1.1 channels, which help to sustain plateau potentials. The gradual
repolarization during plateau potentials causes CaV1.1 channels to close prior to termination of the potential. Rapid, voltage-dependent closing of Na+
channels in the NaPIC mode contributes to termination of plateau potentials. ACh = acetylcholine.

difference between these values is close to 44 mV. In ClCadr muscle, the mean membrane potential
prior to termination of plateau potentials was 46 mV, and in 9-AC treated muscle it was 45 mV.
Thus, a mean membrane potential of 44 mV appears to predict both entry into, as well as termination of, plateau potentials.
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Both Cav1.1 and Nav1.4 are voltage-gated channels that could depolarize muscle to potentials
achieved during plateau potentials. In spinal motor neurons, CaV1.3 channels play a central role
in the generation of plateau potentials that last many seconds (Alaburda et al., 2002; Heckman and
Enoka, 2012; Hounsgaard, 2017). Here, we show that the development of plateau potentials was
not affected in ncDHPR muscle that lack Ca2+ current through Cav1.1. However, there was a reduction in the duration of plateau potentials in ncDHPR muscle. These data suggest that Ca2+ flux
through Cav1.1 channels contributes to sustaining plateau potentials. This was a surprise, as the
membrane potential during plateau potentials is more negative than voltages at which there is significant current through CaV1.1 channels (Garcı́a and Beam, 1994; Bannister and Beam, 2013).
One explanation is that in intact, mature fibers, prolonged depolarization during plateau potentials
allows for activation of CaV1.1 at more negative potentials than during the shorter step depolarizations typically used for voltage clamp studies. Our findings suggest that despite Ca2+ current
through CaV1.1 having no essential role in healthy muscle (Dayal et al., 2017), it may contribute to
pathologic depolarization in muscle channelopathies. It is not clear at this point whether the primary
role of Ca2+ flux through CaV1.1 channels in prolonging plateau potentials is a direct effect of
increased Ca2+ conductance or whether it is due to effects of Ca2+ accumulation on other ion
channels.
Partial block of Nav1.4 channels with ranolazine eliminated plateau potentials, suggesting involvement of NaV1.4. However, the majority of Nav1.4 channels inactivate within ms (fast-inactivating
NaV1.4 channels), such that they cannot contribute to prolonged depolarization during plateau
potentials. There is a NaPIC in skeletal muscle that appears to arise from modal gating whereby,
with very low frequency, any NaV1.4 channel may enter the non-inactivating mode (Patlak and Ortiz,
1986; Gage et al., 1989; Hawash et al., 2017). The subset of NaV1.4 channels in the non-activating
mode appears to play a role in the development of plateau potentials.
Ranolazine has been found to preferentially block NaPIC (El-Bizri et al., 2011; Kahlig et al.,
2014). When myotonic muscle was treated with ranolazine to block NaPIC, depolarization of the
mean membrane potential during repetitive firing was decreased and plateau potentials were prevented. An important contributor was lessening of depolarization of the membrane potential during
the interspike interval. Previously, the only identified contributor to depolarization of the interspike
membrane potential was K+ build-up in the transverse (t)-tubules (invaginations of the sarcolemma),
which depolarizes the K+ equilibrium potential (Adrian and Bryant, 1974; Adrian and Marshall,
1976; Wallinga et al., 1999; Fraser et al., 2011). The finding that block of NaPIC lessens depolarization of the interspike membrane potential suggests that NaPIC is activated during this interval.
We hypothesize that activation of NaPIC combines with K+ build-up in t-tubules to depolarize
muscle to a mean membrane potential of 44 mV during myotonia, such that a plateau potential is
triggered. An additional contributor to this depolarization may be the lessening of inward rectifier
potassium channel (Kir) conductance with depolarization (Standen and Stanfield, 1980; Struyk and
Cannon, 2008). It is unclear whether NaPIC, K+ build-up, and decreased Kir conductance can fully
account for depolarization during plateau potentials. Based on the studies of sustained depolarizations (sometimes termed plateau potentials) in neurons, a family of ion channels that might contribute is the transient receptor potential (TRP) ion channel family (Yan et al., 2009; Phelan et al.,
2012). Members of the TRP ion channel family are expressed in skeletal muscle (Brinkmeier, 2011;
Gailly, 2012), and we recently found that activation of TRPV4 plays a role in triggering percussion
myotonia (Dupont et al., 2020).
While entry into plateau potentials was often gradual (Figure 4), it could also occur over two to
four action potentials (~100–200 ms, Figure 2, Figure 4). Repolarization occurred over 200–300 ms.
While we do not know all the channels involved, we hypothesize one contributor to the instances of
rapid onset and termination of plateau potentials is activation and deactivation of NaPIC (Figure 9).
NaPIC in muscle can activate and deactivate within 10 ms (Gage et al., 1989). The impression that
gating of NaPIC is slow comes from the slow ramp protocols often used to study NaPIC. These protocols enable inactivation of fast Na current such that NaPIC can be studied in isolation
(Hawash et al., 2017).
Ion channels promoting repolarization are likely also involved in the sudden termination of plateau potentials. Oscillations in membrane potential often occurred at the beginning or end of plateau potentials. In motor neurons, oscillations in membrane potential are caused by a balance
between two voltage-gated ion channels: one promoting depolarization and one promoting
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hyperpolarization (Iglesias et al., 2011; Sciamanna and Wilson, 2011; Nardelli et al., 2017). Kv
channels could participate in oscillations occurring during plateau potentials given that Kv conductance in muscle is large and the channels begin to activate at voltages reached during plateau
potentials (Beam and Donaldson, 1983; DiFranco et al., 2012). Thus, it may be possible to prevent
plateau potentials by combining partial block of channels promoting depolarization such as NaPIC
with partial opening of channels promoting repolarization such as Kv channels.
As an example of how such an approach might work, plateau potentials in 9AC treated muscle
were significantly shorter than in ClCadr muscle. Two factors may explain the difference. The first is
that ClC-1 conductance is not completely blocked following application of 100 mM 9-AC
(Palade and Barchi, 1977). While small, the remaining current through ClC-1 channels promotes
repolarization and shortens plateau potentials. The second is that NaPIC current is larger in ClCadr
muscle compared to wild-type muscle (used for the 9-AC model of myotonia) (Hawash et al., 2017).
The combination of slightly higher ClC-1 conductance and slightly smaller NaPIC likely combine to
shorten plateau potentials in the 9-AC model of myotonia. However, despite the shorter duration of
plateau potentials in the 9-AC model of myotonia, they were more frequent (92% of fibers vs 30% of
fibers). The reason for this difference is not known and raises the possibility that currents not yet
identified play a role in development of plateau potentials.

Blocking NaPIC as therapy for transient weakness
In a mouse model of myotonia congenita, ranolazine prevents both development of plateau potentials in vitro and transient weakness in vivo. In open label trials of ranolazine in both myotonia congenita and paramyotonia congenita, there were statistically significant reductions in the degree of selfreported weakness (Arnold et al., 2017; Lorusso et al., 2019). Taken together, these data suggest
that the clinical benefit of blocking Na+ channels in some diseases with myotonia may result, in part,
from prevention of transient weakness secondary to development of plateau potentials. Our data
also raises the possibility that blocking of Cav1.1 channels might reduce transient weakness by shortening the duration of plateau potentials. Since blockers of L-type Ca2+ channels are used clinically to
treat hypertension and have few side effects, a trial of their efficacy in reducing transient weakness
may be worthwhile.
Mutations of NaV1.4 responsible for hyperkalemic periodic paralysis increase NaPIC
(Cannon et al., 1991; Cannon and Strittmatter, 1993a), which appears to play a central role in triggering the depolarization that underlies attacks of transient weakness (Lehmann-Horn et al., 1987;
Jurkat-Rott et al., 2010; Cannon, 2015). This suggests that blocking NaPIC should be effective in
treating hyperkalemic periodic paralysis. However, treating patients with Na+ channel blockers that
are effective in treating myotonia, such as mexiletine, was previously found to be ineffective
(Ricker et al., 1983; Ricker et al., 1986). The finding that blocking NaPIC with ranolazine lessens
depolarization of the interspike membrane potential suggests it might be worth considering a trial
of this FDA-approved drug’s efficacy in hyperkalemic periodic paralysis.

Conclusion
We identified currents contributing to plateau potentials that are responsible for transient weakness
in recessive myotonia congenita. We also determined that blocking a current contributing to plateau
potentials provided effective amelioration of transient weakness. Currents contributing to plateau
potentials are present in wild-type muscle; thus, they might contribute to depolarization in other
muscle channelopathies with transient weakness, such as hyper- and hypokalemic periodic paralysis.
Identification of channels involved in generation of plateau potentials in skeletal muscle may thus
advance understanding of regulation of excitability in both healthy and diseased muscle.

Materials and methods
Key resources table
Reagent type (species) or resource
Strain, strain background (Mus musculus)

Designation
adr-mto

Clcn1

adr

/J (ClC

) mice

Source or reference

Identifiers

Jackson Labs

Stock #000939

Additional information

Continued on next page
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Continued
Reagent type (species) or resource

Designation

Source or reference

Identifiers

Additional information

Strain, strain background (Mus musculus)

ncDHPR mice

Dayal et al., 2017
Nat Commun 8:475.

Chemical compound, drug

9-Anthracene-carboxylic acid (9-AC)

Sigma

Cat. #: A4678

0.1 mM

Chemical compound, drug

N-benzyl-p-toluenesulfonamide (BTS)

TCI America

Prod. #: B3082

0.05 mM

Chemical compound, drug

Ranolazine

Sigma-Aldrich

Cat. #: R6152

0.04 mM

Chemical compound, drug

Tetrodotoxin (TTX)

Tocris

Cat. #: 1069

0.001 mM

Chemical compound, drug

3,4-diaminopyridine (3,4-DAP)

Sigma-Aldrich

Cat. #:
D7148

0.1 mM

Chemical compound, drug

Ouabain

Sigma-Aldrich

Cat. #: 03125

Software, algorithm

Spike2

http://ced.co.uk/down
loads/latestsoftware

Software, algorithm

MATLAB

https://www.mathworks
.com/downloads

0.01 mM
Version 8

Mice
All animal procedures were performed in accordance with the policies of the Animal Care and Use
Committee of Wright State University and were conducted in accordance with the United States
Public Health Service’s Policy on Humane Care and Use of Laboratory Animals.
The genetic mouse model of myotonia congenita used was Clcn1adr-mto/J (ClCadr) mice, which
have a homozygous null mutation in the Clcn1 gene (Jackson Laboratory Stock #000939). The pharmacologic model of Becker disease involved treatment of muscle with 100 mM 9-anthracenecarboxylic acid (9-AC). The mouse model of Ca2+ non-conducting CaV1.1 used was ncDHPR, carrying a
point mutation in the Cacna1S gene coding for N617D in pore loop II (Dayal et al., 2017).
Genotyping of ClCadr mice was performed as previously described to select heterozygous mice
for breeding (Dupont et al., 2019). Otherwise, homozygous myotonic mice were identified by
appearance and behavior as previously described (Novak et al., 2015). Unaffected littermates were
used as controls. Genotyping for selection of homozygous ncDHPR was performed as previously
described (Dayal et al., 2017). Both male and female mice were used from 2 months to 6 months of
age. As mice with myotonia have difficulty climbing to reach food, symptomatic mice were supplied
with moistened chow paste (Irradiated Rodent Diet; Harlan Teklad 2918) on the floor of the cage.

Electrophysiology
Current and voltage clamp recordings were performed at 20–22˚C.

Current clamp
Mice were sacrificed using CO2 inhalation followed by cervical dislocation, and both extensor digitorum longus (EDL) muscles were dissected out tendon-to-tendon. Muscles were maintained and
recorded at 22˚C within 6 hr of sacrifice. The recording chamber was continuously perfused with
Ringer solution containing (in mM) NaCl, 118; KCl, 3.5; CaCl2, 1.5; MgSO4, 0.7; NaHCO3, 26.2;
NaH2PO4, 1.7; glucose, 5.5 (pH 7.3–7.4 at 20–22˚C), and equilibrated with 95% O2 and 5% CO2.
Intracellular recordings were performed as previously described (Novak et al., 2015;
Hawash et al., 2017; Dupont et al., 2019). Briefly, muscles were loaded with 50 mM N-benzyl-p-toluenesulfonamide (BTS, Tokyo Chemical Industry) for at least 30 min prior to recording to prevent
contraction. BTS was dissolved in DMSO and added to the perfusate prior to bubbling with 95% O2
and 5% CO2, as we have found that BTS is more soluble at a basic pH. Prior to recording, muscles
were stained for 3 min with 10 mM 4-(4-diethylaminostyrl)-N-methylpyridinium iodide (4-Di-2ASP,
Molecular Probes) to allow imaging muscle with an upright epifluorescence microscope (Leica DMR,
Bannockburn, IL).
Micro-electrodes were filled with 3M KCl solution containing 1 mM sulforhodamine to visualize
the electrodes with epifluorescence. Resistances were between 15 and 30 MW, and capacitance
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compensation was optimized prior to recording. Fibers with resting potentials more depolarized
than –74 mV were excluded from analysis.
In cases where there was failure of action potentials during trains of stimulation, we did not determine whether the failure was due to the presence of an absolute or relative refractory period by
altering current injection during the train of stimuli. Successful repolarization following a plateau
potential was defined as a return to within 4 mV of the resting potential prior to the plateau potential. Fibers that did not fully repolarize may have become damaged and were thus discarded from
further analysis.

Voltage clamp
Flexor digitorum brevis (FDB) and interosseous (IO) muscle fibers were isolated as previously
described (Waters et al., 2013; Hawash et al., 2017). Briefly, muscles were surgically removed and
enzymatically dissociated at 37˚C under mild agitation for ~1 hr using 1000 U/mL of collagenase
type IV (Worthington Biochemical). Mechanical dissociation was completed using mild trituration in
buffer with no collagenase. The fibers were allowed to recover at 20–22˚C for 1 hr before being
used for electrical measurements.
Both the current-passing and voltage-sensing electrodes were filled with internal solution (see
below) and had resistances of ~15 MW. After impalement, 10 min of hyperpolarizing current injection
was allowed for equilibration of the electrode solution. Data were acquired at 20 kHz and low-pass
filtered with the internal Axoclamp 900A filters at 1 kHz. The voltage clamp command signal was
low-pass filtered with an external Warner LFP-8 at 1 kHz.
Internal solution (in mM) was as follows: 75 aspartate, 30 EGTA, 15 Ca(OH)2, 5 MgCl2, 5 ATP diNa, five phosphocreatine di-Na, five glutathione, 20 MOPS, and pH 7.2 with CsOH.
Extracellular solution (in mM) was as follows: 144 NaCl, 4 CsCl, 1.2 CaCl2, 0.6 MgCl2, five glucose,
1 NaH2PO4, 10 MOPS, 0.05 BaCl2, 0.1 9-AC, 0.001 TTX, 0.01 Ouabain, 0.1 3,4-diaminopyridine (3,4DAP), and pH 7.4 with NaOH.

In vivo muscle force recording
In vivo muscle force recordings were performed as previously described (Dupont et al., 2019;
Wang et al., 2020). Briefly, mice were anesthetized via isoflurane inhalation; then the distal tendon
of the triceps surae muscles was attached to a force transduction motor and the sciatic nerve was
stimulated while isometric muscle force generation was measured. The sciatic nerve was stimulated
with constant current injection. The amplitude of the current pulse was adjusted to 150% of the current required to trigger a single action potential. To induce myotonia, 45 pulses of 1 ms duration
were delivered at 100 Hz. To follow the development of transient weakness, 15 pulses delivered at
100 Hz were delivered every 4 s. Muscle temperature was monitored with a laser probe and maintained between 29˚C and 31˚C with a heat lamp. The muscle was kept moist by applying mineral oil.
Ranolazine was administered via intraperitoneal (i.p.) injection at a dose of 50 mg/kg dissolved in
water. The typical volume of water injected was 100 ml.

Statistics
Sample size was determined by past practice, where we have found that an n of 5 muscles from five
different mice, studied on different days, yields statistically significant differences in muscle action
potential properties. At least five muscle fibers were recorded from each muscle. However, for studies of plateau potentials in ClCadr mice we obtained recordings with adequate preservation of resting membrane potential in only a subset of fibers, so fewer fibers per muscle were included in the
final analysis. This was due to the prolonged duration of plateau potentials, which required maintaining prolonged impalement of individual fibers with two electrodes. No outlier data points were
excluded. Intracellular recording data from different mice were analyzed using nested analysis of variance with n as the number of mice, with data presented as mean ± SD. p<0.05 was considered to
be significant. The numbers of animals and fibers used are described in the corresponding figure
legends and text. For parameters that were not normally distributed, such as duration of the plateau
potential and slope of the repolarization, differences between two data sets were analyzed after
applying a log transformation, which yielded normally distributed data.
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For comparisons of data within individual muscle fibers (mean membrane potential and mean firing rate for runs of myotonia, without and with plateau potentials), the paired Student’s t-test was
used with n as the number of fibers. For force recording comparisons before and after ranolazine
treatment, the paired Student’s t-test was used with n as the number of mice. For comparisons of
force recordings between myotonic mice and unaffected littermates, a two-sample Student’s t-test
was used.
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weakness and compound muscle action potential decrement in Myotonia congenita. Muscle & Nerve 21:1334–
1337. DOI: https://doi.org/10.1002/(SICI)1097-4598(199810)21:10<1334::AID-MUS16>3.0.CO;2-1, PMID:
9736066
DiFranco M, Quinonez M, Vergara JL. 2012. The delayed rectifier potassium conductance in the sarcolemma and
the transverse tubular system membranes of mammalian skeletal muscle fibers. Journal of General Physiology
140:109–137. DOI: https://doi.org/10.1085/jgp.201210802

Myers et al. eLife 2021;10:e65691. DOI: https://doi.org/10.7554/eLife.65691

20 of 23

Research article

Medicine Neuroscience
Drost G, Blok JH, Stegeman DF, van Dijk JP, van Engelen BG, Zwarts MJ. 2001. Propagation disturbance of
motor unit action potentials during transient paresis in generalized myotonia: a high-density surface EMG
study. Brain 124:352–360. DOI: https://doi.org/10.1093/brain/124.2.352, PMID: 11157562
Dupont C, Denman KS, Hawash AA, Voss AA, Rich MM. 2019. Treatment of myotonia congenita with retigabine
in mice. Experimental Neurology 315:52–59. DOI: https://doi.org/10.1016/j.expneurol.2019.02.002,
PMID: 30738808
Dupont C, Novak K, Denman K, Myers JH, Sullivan JM, Walker PV, Brown NL, Ladle DR, Bogdanik L, Lutz CM, A
Voss A, Sumner CJ, Rich MM. 2020. TRPV4 antagonism prevents mechanically induced myotonia. Annals of
Neurology 88:297–308. DOI: https://doi.org/10.1002/ana.25780, PMID: 32418267
El-Bizri N, Kahlig KM, Shyrock JC, George AL, Belardinelli L, Rajamani S. 2011. Ranolazine block of human na v 1.
4 sodium channels and paramyotonia congenita mutants. Channels 5:161–172. DOI: https://doi.org/10.4161/
chan.5.2.14851, PMID: 21317558
Fraser JA, Huang CL-H, Pedersen TH. 2011. Relationships between resting conductances, excitability, and
t-system ionic homeostasis in skeletal muscle. Journal of General Physiology 138:95–116. DOI: https://doi.org/
10.1085/jgp.201110617
Gage PW, Lamb GD, Wakefield BT. 1989. Transient and persistent sodium currents in normal and denervated
mammalian skeletal muscle. The Journal of Physiology 418:427–439. DOI: https://doi.org/10.1113/jphysiol.
1989.sp017850, PMID: 2559972
Gailly P. 2012. TRP channels in normal and dystrophic skeletal muscle. Current Opinion in Pharmacology 12:326–
334. DOI: https://doi.org/10.1016/j.coph.2012.01.018, PMID: 22349418
Garcı́a J, Beam KG. 1994. Measurement of calcium transients and slow calcium current in myotubes. Journal of
General Physiology 103:107–123. DOI: https://doi.org/10.1085/jgp.103.1.107
Hawash AA, Voss AA, Rich MM. 2017. Inhibiting persistent inward sodium currents prevents myotonia. Annals of
Neurology 82:385–395. DOI: https://doi.org/10.1002/ana.25017, PMID: 28833464
Heckman CJ, Enoka RM. 2012. Motor unit. Comprehensive Physiology 2:2629–2682. DOI: https://doi.org/10.
1002/cphy.c100087, PMID: 23720261
Hounsgaard J. 2017. Motor neurons. Comprehensive Physiology 7:463–484. DOI: https://doi.org/10.1002/cphy.
c160025, PMID: 28333379
Iglesias C, Meunier C, Manuel M, Timofeeva Y, Delestrée N, Zytnicki D. 2011. Mixed mode oscillations in mouse
spinal motoneurons arise from a low excitability state. Journal of Neuroscience 31:5829–5840. DOI: https://doi.
org/10.1523/JNEUROSCI.6363-10.2011, PMID: 21490224
Jurkat-Rott K, Holzherr B, Fauler M, Lehmann-Horn F. 2010. Sodium channelopathies of skeletal muscle result
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